Pharmacodynamic Study of L-Arginine on Lactate in Brain Metastases

A proof-of-concept clinical trial dataset from 20 patients with solid tumor brain metastases. The study measured the rapid effects of intravenous L-arginine doses on lactate metabolism using magnetic resonance spectroscopy. Data was published by Xueping Liu on figshare under a CC-BY-4.0 license and last updated in May 2026.

Use Cases

• Analyzing dose-response relationships for lactate reduction based on the 10g, 20g, and 30g L-arginine dose groups.
• Modeling the temporal pharmacodynamic profile of lactate suppression based on serial MRS measurements at baseline and post-infusion timepoints.
• Hypothesis generation for future clinical trial designs based on the proposed '30g L-arginine followed by radiotherapy within 30 minutes' regimen.

Strengths

• Data is from a completed clinical trial with 20 patients and a clear primary endpoint (lactate reduction at T3).
• Results show a statistically significant lactate reduction (median ΔLac_T3: -1.09 vs. 0.00, p=0.0012) in the pooled treatment group.
• The 30g dose group demonstrated a peak lactate reduction of 63.5% at 30 minutes with a strong correlation (ρ = -0.753, p<0.001).
• No treatment-related adverse events were reported up to 24 hours post-infusion.

Limitations

• Row count and column-level documentation are unknown, which limits suitability assessment.
• The dataset is small (39.8 KB), indicating limited scope, likely containing summary results rather than individual patient-level data.
• As a proof-of-concept study, clinical benefits require confirmation in larger randomized controlled trials.

Provenance

Source

figshare, author Xueping Liu.

Collection Method

Data originates from a randomized clinical trial (ChiCTR2400080841) using serial magnetic resonance spectroscopy.

Time Range

The study period is not specified, but data reflects measurements at baseline and multiple post-infusion timepoints (approximately 19–36 minutes).

Freshness

Last updated 2026-05-28 04:44:25.